|
1.
|
|
8 p, 535.7 KB |
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
/
Joensuu, Heikki (Helsinki University Hospital) ;
Blay, Jean-Yves (University Claude Bernard Lyon I) ;
Comandone, Alessandro (Gradenigo Hospital) ;
Martin-Broto, Javier (Hosp o Virgen del Rocío (Sevilla, Andalusia)) ;
Fumagalli, Elena (Fondazione IRCCS Istituto Nazionale Dei Tumori) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Del Muro, Xavier Garcia (Hospital Universitari de Bellvitge) ;
Adenis, Antoine (Centre Oscar Lambret) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Bouche, Olivier (University Hospital Robert Debre) ;
Italiano, Antoine (Comprehensive Cancer Centre. 2Institut Bergonie) ;
Bauer, Sebastian (University of Duisburg- Essen) ;
Barone, Carlo (University Hospital A. Gemelli) ;
Weiss, Claudia (Novartis Pharma GmbH) ;
Crippa, Stefania (Novartis Farma) ;
Camozzi, Maura (Novartis Farma) ;
Castellana, Ramon (Novartis Farmaceutica SA) ;
Le Cesne, Axel (Gustave Roussy) ;
Universitat Autònoma de Barcelona
This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. [...]
2017 -  10.1038/bjc.2017.290
British Journal of Cancer, Vol. 117 Núm. 9 (2017) , p. 1278-1285
|
|
|
2.
|
|
17 p, 345.4 KB |
Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
/
Casali, P.G. (University of Milan) ;
Bielack, Stefan S (Klinikum Stuttgart-Olgahospital) ;
Abecassis, N. (Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE) ;
Aro, H.T. (Turku University Hospital (Turun Yliopistollinen Keskussairaala)) ;
Bauer, S. (University Hospital Essen (Alemanya)) ;
Biagini, Roberto (Regina Elena National Cancer Institute) ;
Bonvalot, S. (Institut Curie) ;
Boukovinas, I. (Bioclinic Thessaloniki) ;
Bovee, J.V.M.G. (Leiden University Medical Center) ;
Brennan, B. (Royal Manchester Children's Hospital) ;
Brodowicz, Thomas (Medizinische Universität Wien) ;
Broto, J.M. (Hospital Universitario Virgen Del Rocio-CIBERONC) ;
Brugières, L. (Gustave Roussy Cancer Campus) ;
Buonadonna, A. (Centro di Riferimento Oncologico di Aviano) ;
De Alava, E (Universidad de Sevilla) ;
Dei Tos, A.P. (Ospedale Regionale di Treviso S.Maria di Cà Foncello) ;
Del Muro, X.G. (Integrated Unit ICO Hospitalet) ;
Dileo, P. (University College London Hospitals NHS Trust) ;
Dhooge, C. (Universitair Ziekenhuis Gent) ;
Eriksson, M. (Skåne University Hospital (Suècia)) ;
Fagioli, F. (University of Turin) ;
Fedenko, A. (N. N. Blokhin Russian Cancer Research Center) ;
Ferraresi, V. (Regina Elena National Cancer Institute) ;
Ferrari, A. (Fondazione IRCCS Istituto Nazionale Dei Tumori) ;
Ferrari, S. (Istituto Ortopedico Rizzoli) ;
Frezza, A.M. (Istituto Nazionale Dei Tumori) ;
Gaspar, N. (Gustave Roussy Cancer Campus) ;
Gasperoni, S. (Azienda Ospedaliera Universitaria Careggi Firenze) ;
Gelderblom, H. (Leiden University Medical Centre) ;
Gil, T. (Institut Jules Bordet) ;
Grignani, G. (Candiolo Cancer Institute) ;
Gronchi, A. (University of Milan) ;
Haas, R.L. (Leiden University Medical Centre) ;
Hassan, B. (Oxford University Hospitals NHS Foundation Trust) ;
Hecker-Nolting, S. (Klinikum Stuttgart-Olgahospital) ;
Hohenberger, P. (Mannheim University Medical Center) ;
Issels, R. (University Munich) ;
Joensuu, H. (Helsinki University Central Hospital (HUCH)) ;
Jones, R.L. (Royal Marsden Hospital (Regne Unit)) ;
Judson, I. (Institute of Cancer Research) ;
Jutte, P. (University Medical Center Groningen) ;
Kaal, S. (Radboud University Medical Center) ;
Kager, L. (St. Medical University Vienna) ;
Kasper, B. (Mannheim University Medical Center) ;
Kopeckova, K. (University Hospital Motol) ;
Krákorová, D.A. (Masaryk Memorial Cancer Institute) ;
Ladenstein, R. (Medical University Vienna) ;
Le Cesne, A. (Gustave Roussy Cancer Campus) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Lugowska, I. (Maria Skłodowska Curie Institute-Oncology Centre) ;
Merimsky, O. (Tel Aviv Sourasky Medical Center (Ichilov)) ;
Montemurro, M. (Medical Oncology University Hospital of Lausanne) ;
Morland, B. (Birmingham Women's and Children's NHS Foundation Trust) ;
Pantaleo, M.A. (Policlinico S Orsola-Malpighi Università di Bologna) ;
Piana, R. (University of Turin) ;
Picci, P. (Istituto Ortopedico Rizzoli) ;
Piperno-Neumann, S. (Institut Curie) ;
Reichardt, P. (Helios Klinikum Berlin Buch) ;
Robinson, M.H. (Weston Park Hospital NHS Trust) ;
Rutkowski, P. (Maria Skłodowska Curie Institute-Oncology Centre) ;
Safwat, A.A. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Schöffski, P. (University Hospitals Leuven (Bèlgica)) ;
Sleijfer, S. (Erasmus MC Cancer Institute) ;
Stacchiotti, S. (Istituto Nazionale Dei Tumori) ;
Strauss, S.J. (University College London Hospitals NHS Trust) ;
Sundby Hall, K. (Norwegian Radium Hospital) ;
Unk, M. (Institute of Oncology of Ljubljana) ;
Van Coevorden, F. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ;
Van Der Graaf, W.T.A. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ;
Whelan, J. (Sarcoma Unit. University College London Hospitals NHS Trust) ;
Wardelmann, E. (Universitätsklinikum Münster) ;
Zaikova, O. (Oslo University Hospital (Oslo, Noruega)) ;
Blay, Jean-Yves (Centre Leon Bernard and UCBL1) ;
Universitat Autònoma de Barcelona
2018 - 10.1093/annonc/mdy310
Annals of oncology, Vol. 29 (january 2018) , p. iv79-iv95
|
|
|
3.
|
|
11 p, 529.4 KB |
Nivolumab and sunitinib combination in advanced soft tissue sarcomas : A multicenter, single-arm, phase Ib/II trial
/
Martin-Broto, J. (Universidad de Sevilla) ;
Hindi, Nadia (Universidad de Sevilla) ;
Grignani, G. (Candiolo Cancer Institute) ;
Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ;
Redondo, A. (Hospital Universitario La Paz (Madrid)) ;
Valverde, Claudia (Vall d'Hebron Institut d'Oncologia) ;
Stacchiotti, S. (Istituto Nazionale Tumori) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
D'Ambrosio, L. (Candiolo Cancer Institute) ;
Gutierrez, A. (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Perez-Vega, H. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Encinas-Tobajas, V. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
De Álava, Enrique (Universidad de Sevilla) ;
Collini, Paola (Istituto Nazionale Tumori) ;
Peña-Chilet, M. (Hospital Virgen Del Rocio) ;
Dopazo, J. (Hospital Virgen Del Rocío) ;
Carrasco-Garcia, I. (Universidad de Sevilla) ;
Lopez-Alvarez, M. (Universidad de Sevilla) ;
Moura, D.S. (Universidad de Sevilla) ;
Lopez-Martin, Jose A (Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12)) ;
Universitat Autònoma de Barcelona
Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. [...]
2020 - 10.1136/jitc-2020-001561
Journal for immunotherapy of cancer, Vol. 8 Núm. 2 (17 2020) , p. e001561
|
|
|
4.
|
|
12 p, 682.4 KB |
Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
/
Hidalgo-Ríos, Samuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Carrillo García, Jaime (Hospital Universitario General de Villalba. Servicio de Oncología Médica) ;
Moura, David S. (Hospital Universitario General de Villalba. Servicio de Oncología Médica) ;
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Redondo, Andrés (Hospital Universitario La Paz. Servicio de Oncología Médica. Instituto de Investigación en Salud (IdiPAZ)) ;
Italiano, Antoine (Institut Bergonié. Department of Oncology) ;
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Hindi, Nadia (Hospital Universitario Fundación Jiménez Díaz. Servicio de Oncología Médica) ;
López-Guerrero, J.A (Laboratory of Molecular Biology. Fundación Instituto Valenciano de Oncología) ;
Garcia del Muro, Xavier (Institut d'Investigació Biomèdica de Bellvitge) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet. Servicio de Oncología Médica) ;
Palmerini, Emanuela (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Bernabeu, Daniel (Hospital Universitario La Paz. Sección de Radiología musculoesquelética) ;
Le Cesne, Axel (Gustave Roussy Cancer Campus. Department of Medical Oncology) ;
Casali, Paolo Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori. Adult Mesenchymal and Rare Tumor Unit. Department of Cancer Medicine) ;
Blay, Jean-Yves (Department of Medical Oncology. Centre Léon Bérard. Université Claude Bernard Lyon) ;
Cruz-Jurado, Josefina (Hospital Universitario de Canarias. Servicio de Oncología Médica) ;
Martín-Broto, Javier (Hospital Universitario Fundación Jiménez Díaz. Servicio de Oncología Médica)
Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. [...]
2022 - 10.3390/cancers14174186
Cancers, Vol. 14 Núm. 17 (september 2022) , p. 4186
|
|
|
5.
|
|
14 p, 2.6 MB |
Epithelioid hemangioendothelioma, an ultra-rare cancer : a consensus paper from the community of experts
/
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Miah, Aisha B. (The Royal Marsden Hospital) ;
Frezza, Anna Maria (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Messiou, Christina (Department of Radiology. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Morosi, Carlo (Radiology Department. Fondazione IRCCS Istituto Nazionale Tumori) ;
Caraceni, Augusto (Fondazione IRCCS Istituto Nazionale Tumori) ;
Antonescu, Cristina (Memorial Sloan Kettering Cancer Center) ;
Bajpai, Jyoti (Homi Bhabha National Institute. Medical Oncology Department) ;
Baldini, Elizabeth Healey (Dana-Farber Cancer Center/Brigham) ;
Bauer, Sebastian (University of Duisburg-Essen) ;
Biagini, Roberto (Regina Elena National Cancer Institute) ;
Bielack, Stefan S. (Klinikum Stuttgart - Olgahospital) ;
Blay, Jean-Yves (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer) ;
Bonvalot, Sylvie (Institut Curie. Department of Surgical Oncology) ;
Boukovinas, Ioannis P. (Nordix) ;
Bovee, Judith V.M.G. (Leiden University Medical Center) ;
Boye, Kjetil (The Norwegian Radium Hospital) ;
Brodowicz, Thomas (Medical University Vienna) ;
Callegaro, Dario (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
De Álava, Enrique (Department of Normal and Pathological Cytology and Histology. School of Medicine. University of Seville) ;
Deoras-Sutliff, M. (The EHE Foundation) ;
Dufresne, Armelle (Department of Medical Oncology. Centre Leon Berard. Université Claude Bernard Lyon. Unicancer) ;
Eriksson, Mikael (Department of Oncology. Skane University Hospital and Lund University) ;
Errani, Costantino (Orthopaedic Service. Musculoskeletal Oncology Department. IRCCS Istituto Ortopedico Rizzoli) ;
Fedenko, Alexander (Medical Oncology Division. P.A. Herzen Cancer Research Institute) ;
Ferraresi, Virginia (Sarcomas and Rare Tumors Unit. IRCCS Regina Elena National Cancer Institute) ;
Ferrari, Andrea (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Fletcher, Christopher D.M. (Department of Pathology Brigham & Women's Hospital) ;
Garcia del Muro, Xavier (Universitat de Barcelona) ;
Gelderblom, Hans J. (Department of Medical Oncology. Leiden University Medical Center) ;
Gladdy, Rebecca A. (University of Toronto and Lunenfeld-Tanenbaum Research Institute) ;
Gouin, François (Department of Surgery. Centre Leon Berard) ;
Grignani, Giovanni (Candiolo Cancer Institute. FPO - IRCCS) ;
Gutkovich, J. (NUY Langone Medical Center) ;
Haas, Rick (Department of Radiotherapy. the Leiden University Medical Center) ;
Hindi, Nadia (Universidad de Sevilla. Instituto de Biomedicina de Sevilla) ;
Hohenberger, Peter (Mannheim University Medical Center) ;
Huang, Paul (Division of Molecular Pathology. The Institute of Cancer Research) ;
Joensuu, Heikki T. (Department of Oncology. Helsinki University Hospital & Helsinki University) ;
Jones, Robin Lewis (Department of Cancer. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Jungels, Christiane (Institut Jules Bordet. Université Libre de Bruxelles) ;
Kasper, Bernd (University of Heidelberg. Mannheim University Medical Center. Sarcoma Unit) ;
Kawai, Akira (Musculoskeletal Oncology and Rehabilitation Medicine. Rare Cancer Center National Cancer Center Hospital) ;
Le Cesne, Axel (International Department. Gustave Roussy) ;
Le Grange, Franél (UCLH - University College London Hospitals NHS Foundation Trust) ;
Leithner, Andeas (Department of Orthopaedics and Trauma Medical University Graz) ;
Leonard, H. (Chair of Trustees of the EHE Rare Cancer Charity (UK). Charity number 1162472) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Martin Broto, Javier (Hospital Universitario Fundación Jiménez Díaz) ;
Merimsky, Ofer (Unit of Soft Tissue and Bone Oncology. Division of Oncology. Tel-Aviv Medical Center affiliated with Sackler School of Medicine. Tel Aviv University) ;
Merriam, Priscilla (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology) ;
Miceli, Rosalba (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Mir, Olivier (Sarcoma Group. Gustave Roussy) ;
Molinari, Massimo (University of Pittsburgh Medical Center. Thomas Starzl Transplant Institute) ;
Montemurro, Michael (Oncology. CHUV Lausanne) ;
Oldani, Graziano (Division of Abdominal Surgery. University Hospitals of Geneva) ;
Palmerini, Emanuela (Chemotherapy Unit. IRCCS Istituto Ortopedico Rizzoli) ;
Pantaleo, Maria Abbondanza. (Division of Oncology. IRCCS Azienda Ospedaliero-Universitaria di Bologna) ;
Patel, Sapna Pradyuman (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center) ;
Piperno-Neumann, Sophie (Department of Medical Oncology. Institut Curie) ;
Raut, Chandrajit Premanand (Dana Farber Cancer Center. Harvard Medical School) ;
Ravi, Vinod (Sarcoma Center. The University of Texas M.D. Anderson Cancer Center) ;
Razak, Albiruni Ryan Abdul (Princess Margaret Cancer Centre and Sinai Healthcare System & Faculty of Medicine. University of Toronto) ;
Reichardt, Peter (Helios Klinikum Berlin-Buch. Department of Oncology and Palliative Care) ;
Rubin, Brian P. (Robert J. Tomsich Pathology and Laboratory Medicine Institute. Cleveland Clinic) ;
Rutkowski, Piotr (Maria Sklodowska-Curie National Research Institute of Oncology. Department of Soft Tissue/Bone Sarcoma and Melanoma) ;
Safwat, Akmal Ahmed (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Sangalli, Claudia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Sapisochin, Gonzalo (Multi-Organ Transplant and HPB Surgical Oncology. Division of General Surgery. Department of Surgery. University of Toronto) ;
Sbaraglia, Marta (Department of Pathology. Azienda Ospedaliera Università Padova) ;
Scheipl, Susanne (Department of Orthopaedics and Trauma. Medical University of Graz) ;
Schöffski, Patrick (Leuven Cancer Institute) ;
Strauss, Dirk Cornelius (Department of Surgery. The Royal Marsden Hospital and The Institute of Cancer Research) ;
Strauss, Sandra J. (University College London Hospital) ;
Sundby Hall, Kirsten (Department of Oncology. Oslo University Hospital. The Norwegian Radium Hospital) ;
Tap, William D. (Department of Medicine. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College) ;
Trama, Annalisa (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Tweddle, A. (Palliative Care. The Royal Marsden Hospital and The Institute of Cancer Research London) ;
van der Graaf, Winette T.A. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
van de Sande, Michiel (Department of Orthopedic Surgery Bone and Soft Tissue Tumor Unit. Leiden University Medical Center) ;
Van Houdt, Winan (Sarcoma and Melanoma Unit. The Netherlands Cancer Institute) ;
van Oortmerssen, Gerard (Co-Chair of Sarcoma Patients EuroNet (SPAEN). Woelfersheim. Germany & Chairman of the Dutch organisation for sarcoma patients (Patiëntenplatform Sarcomen). Guest researcher at Leiden University (Leiden Institute for Advanced Computer Science). Leiden University) ;
Wagner, Andrew J. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Department of Medical Oncology) ;
Wartenberg, Markus (Chair of the Board of Directors of Sarcoma Patients EuroNet (SPAEN). Sarcoma Patients EuroNet (SPAEN)) ;
Wood, J. (The Royal Marsden NHS Foundation Trust) ;
Zaffaroni, Nadia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Zimmermann, Camilla (Department of Supportive Care. Princess Margaret Cancer Centre and Division of Palliative Medicine. Department of Medicine. University of Toronto) ;
Casali, Paolo Giovanni (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia)) ;
Dei Tos, Angelo (Department of Pathology. Azienda Ospedaliera Università Padova) ;
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà, Itàlia))
Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a high propensity for systemic involvement. [...]
2021 - 10.1016/j.esmoop.2021.100170
ESMO open, Vol. 6 Núm. 3 (june 2021) , p. 100170
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
